A PHP Error was encountered

Severity: Warning

Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests

Filename: helpers/my_audit_helper.php

Line Number: 176

Backtrace:

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 1034
Function: getPubMedXML

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3152
Function: GetPubMedArticleOutput_2016

File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global

File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword

File: /var/www/html/index.php
Line: 316
Function: require_once

Effect of Dexmedetomidine as an Adjuvant to 0.75% Ropivacaine in Interscalene Brachial Plexus Block Using Nerve Stimulator: A Prospective, Randomized Double-blind Study. | LitMetric

AI Article Synopsis

  • Ropivacaine is a newer local anesthetic that has a better safety profile compared to bupivacaine, while dexmedetomidine is an α agonist used to enhance the effects of local anesthesia.
  • This study examined the effects of adding dexmedetomidine to 0.75% ropivacaine for interscalene brachial plexus blocks in 60 orthopedic surgery patients, split into two randomized groups.
  • Results showed that dexmedetomidine significantly reduced the onset time and extended the duration of both sensory and motor blocks compared to ropivacaine alone.

Article Abstract

Background: Ropivacaine, a newer local anesthetic (LA), has been increasingly used nowadays in different concentrations for peripheral nerve blocks. It has lesser cardiac toxicity and higher safety margin when compared to bupivacaine. Dexmedetomidine, a novel α agonist, is widely used as adjuvant to LA in peripheral nerve blocks to decrease the time of onset and increase the duration of the block. In this study, we evaluated the effect of dexmedetomidine as an adjuvant with 0.75% ropivacaine for interscalene brachial plexus block using nerve stimulator.

Aim: This study aims to know the effect of using dexmedetomidine as an adjuvant to 0.75% ropivacaine in interscalene brachial plexuses block using nerve stimulator.

Settings And Designs: Sixty patients scheduled for elective orthopedic surgery of the upper limb under interscalene block were considered in this prospective randomized controlled double-blind study. The study population was randomly divided into two groups with thirty patients in each group by using computerized randomization.

Materials And Methods: Group R received 30 ml of 0.75% ropivacaine with 0.5 ml normal saline and Group RD received 30 ml of 0.75% ropivacaine with 50 μg of dexmedetomidine. The onset of sensory and motor blocks, duration of sensory and motor block, and patient satisfaction score were observed.

Results: Both the groups were comparable in demographic characteristics. The onset of the sensory and motor block is earlier and statistically significant in Group RD ( < 0.05) when compared to Group R. The duration of sensory and motor blockade were significantly prolonged in Group RD ( < 0.0001).

Conclusion: Addition of dexmedetomidine to 0.75% ropivacaine in interscalene brachial plexus block significantly shortened the time of onset of the block and prolongs the duration sensory and motor blockade.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341687PMC
http://dx.doi.org/10.4103/0259-1162.181431DOI Listing

Publication Analysis

Top Keywords

075% ropivacaine
24
sensory motor
20
ropivacaine interscalene
16
interscalene brachial
16
dexmedetomidine adjuvant
12
adjuvant 075%
12
brachial plexus
12
plexus block
12
block nerve
12
duration sensory
12

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!